Therefore, simultaneously co-targeting the signaling pathways of such as AKT and ERK [5, 22, 39], mTOR and ERK [42], STAT3 and mTOR [43] have been proposed to improve the success of NSCLC targeted therapy. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.